Formulation: A solid
Formal Name: N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl-d4)-benzeneacetamide
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C18H14D4N4O3S2
Formula Weight: 406,5
Shelf life (days): 730
Notes: BAY 57-1293-d4 is intended for use as an internal standard for the quantification of BAY 57-1293 (Item No. 22129) by GC- or LC-MS. BAY 57-1293 is an orally bioavailable helicase-primase inhibitor.{39314} It inhibits the ATPase activity of herpes simplex virus (HSV) helicase-primase (IC50 = 30 nM). It inhibits HSV replication in Vero cells (IC50 = 20 nM for both HSV-1 and HSV-2) and is also active against porcine and bovine HSV strains (IC50s = 5 and 0.12 μM, respectively). In vivo, oral administration of BAY 57-1293 is effective against HSV-1 and HSV-2 in a lethal challenge model (ED50 = 0.5 mg/kg in mice and rats) and in a zosteriform spread model, at a dose of 15 mg/kg, in mice and Lewis rats.{39314,39315} It is also effective in a guinea pig model of genital herpes and a mouse model of ocular herpes. BAY 57-1293 reduces levels of amyloid-beta (Aβ) and phosphorylated Tau in HSV-1 infected Vero cells.{39316}
English
Deutsch
